Search terms included “IL-23” combined with “autoimmune diseases” or “Psoriasis” or “systemic lupus erythematosus (SLE)” or “rheumatoid arthritis (RA)” or “inflammatory bowel disease (IBD)” or “ankylosing spondylitis (AS)” or “nucleic acid aptamer” or “genome editing.” This review mainly elaborates the regulatory mechanism of action and clinical application potential of IL-23 in AD, which would help to further understand IL-23 and provide a theoretical basis for future clinical targeting and drug development. The gene discussed is IL37; the disease is systemic lupus erythematosus.